Diosgenin inhibited the expression of TAZ in hepatocellular carcinoma.

Biochemical and Biophysical Research Communications
Zhize ChenZhongyuan Xia

Abstract

Emerging evidence has supported that TAZ (transcriptional co-activator with PDZ binding motif), one transcription co-activator in Hippo signaling pathway, plays an oncogenic role in liver carcinogenesis. Targeting TAZ could be a potential therapeutic approach for liver cancer patients. In the current study, we aim to determine whether diosgenin could be an inhibitor of TAZ in liver cancer cells. We found that diosgenin inhibited the expression of TAZ in liver cancer cells. Moreover, we found that diosgenin inhibited cell growth, induced apoptosis, suppressed cell migration and invasion in part via inhibition of TAZ in liver cancer cells. Our study provides the evidence to support that diosgenin could be a potential agent for treating human liver cancer.

Citations

Mar 16, 2021·Journal of Ethnopharmacology·Xiaofen LiWenjun Zou
Mar 20, 2021·European Journal of Medicinal Chemistry·Liwei MaWenbao Wang
Sep 4, 2021·The Journal of Steroid Biochemistry and Molecular Biology·Guolong LiWei Li
Nov 10, 2021·Critical Reviews in Food Science and Nutrition·Yifan ZhouBaojun Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.